Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 553-558

  Pan, Huiyun ^a   Liu, Rong ^a   Li, Shengjie ^a   Fang, Hui ^a   Wang, Ziwei ^a   Huang, Sheng ^b   Zhou, Jianying ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

EGFR mutation; Icotinib; Non small lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CROWN ETHER; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOTINIB; QUINAZOLINE DERIVATIVE;

ADULT; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84906245779     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9955-y     Document Type: Article

References (24)

1. Aberle, D. R., & Brown, K. (2008). Lung cancer screening with CT. Clinics in Chest Medicine, 29(1), 1-14.
2. Hua, X., Ward, K. C., Gillespie, T. W., Lipscomb, J., & Goodman, M. (2013). Non-small cell lung cancer treatment receipt and survival among African-Americans and whites in a rural area. Journal of Community Health, 2013, 1-10.
3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine, 346(2), 92-98.
4. Robert, C., Soria, J. C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., et al. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. The lancet Oncology, 6(7), 491-500.
5. Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., et al. (2013). EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. International Journal of Medical Sciences, 10(3), 320-330.
6. Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C. M., et al. (2013). Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute, 105(9), 595-605.
7. Iivanainen, E., Lauttia, S., Zhang, N., Tvorogov, D., Kulmala, J., Grenman, R., et al. (2009). The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvascular Research, 78(3), 278-285.
8. Dongiovanni, D., Daniele, L., Barone, C., Dongiovanni, V., Fissore, C., Sapino, A., et al. (2008). Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer, 61(1), 73-81.
9. Chen, L., He, Y., Huang, H., Liao, H., & Wei, W. (2008). Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical Oncology, 25(2), 161-171.
10. Razis, E., Skarlos, D., Briasoulis, E., Dimopoulos, M., Fountzilas, G., Lambropoulos, S., et al. (2005). Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program. Anti-Cancer Drugs, 16(2), 191-198.
11. Tan, F., Shen, X., Wang, D., Xie, G., Zhang, X., Ding, L., et al. (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76(2), 177-182.
12. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 350(21), 2129-2139.
13. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497-1500.
14. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to Gefitinib and Erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101(36), 13306-13311.
15. Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., et al. (2009). Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE, 4(2), e4576.
16. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology, 11(2), 121-128.
17. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine, 362(25), 2380-2388.
18. Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, S., Wang, D., et al. (2013). Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. The Lancet Oncology, 14(10), 953-961.
19. Piperdi, B., & Perez-Soler, R. (2012). Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs, 72(Suppl 1), 11-19.
20. Fiala, O., Pesek, M., Finek, J., Benesova, L., Bortlicek, Z., & Minarik, M. (2013). Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line Erlotinib versus the reverse sequence. Anticancer Research, 33(8), 3397-3402.
21. Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., et al. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The lancet Oncology, 14(10), 981-988.
22. Costa, D. B., & Kobayashi, S. (2007). Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? British Journal of Cancer, 96(2), 399.
23. Wu, J. Y., Yu, C. J., Yang, C. H., Wu, S. G., Chiu, Y. H., Gow, C. H., et al. (2008). First- or second-line therapy with Gefitinib produces equal survival in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 178(8), 847-853.
24. Ruppert, A. M., Beau-Faller, M., Neuville, A., Guerin, E., Voegeli, A. C., Mennecier, B., et al. (2009). EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. The European Respiratory Journal, 33(2), 436-440.